Royalty Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Royalty Pharma generated cash of $2,987,802,000, which is more than the previous year. Cash used in financing activities reached the amount of -$2,148,754,000 last year. Net change in cash is therefore -$1,233,741,000.
Cash Flow
| 2017 | 1.41B | -1.58B | -123.25M |
|---|---|---|---|
| 2018 | 1.61B | 303.42M | -1.37B |
| 2019 | 1.66B | -2.11B | -1.19B |
| 2020 | 2.03B | -2.75B | 1.48B |
| 2021 | 2.01B | -1.87B | 385.11M |
| 2022 | 2.14B | -1.02B | -944.85M |
| 2023 | 2.98B | -2.07B | -2.14B |
RPRX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.71B | 1.54B | 1.00B | 246M | 1.92B | 1.38B | 1.67B |
Operating activities | |||||||
Net income | 1.13B | 230.06M | 1.24B | 1.70B | 2.46B | 1.51B | 1.34B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 20.49M | 5.67M | 22.99M | 23.05M | 23.92M | 33.26M | 33.26M |
Stock-based compensation expense | 2.35M | 2.17M | 2.44M | 5.42M | 0 | 0 | 0 |
| Deferred income tax benefit | 2.35M | 2.17M | 2.44M | 5.42M | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 1.06M | 31.71M | -29.14M | -400K | 159.86M | 111.52M | -84.48M |
Inventories | 0 | -31.71M | 29.14M | 400K | -166.35M | 0 | 0 |
Accounts payable | 6.23M | 2.28M | -4.58M | -766K | 6.49M | 1.35M | 517K |
Cash generated by operating activities | 2.98B | 2.14B | 2.01B | 2.03B | 1.66B | 1.61B | 1.41B |
Investing activities | |||||||
Purchases Of Investments | -2.11B | -2.56B | -3.59B | -3.93B | -2.36B | -422.40M | -2.30B |
Investments In Property Plant And Equipment | 0 | 2.04B | 523K | 2.19B | -1.72B | 269.59M | -2.29B |
Acquisitions Net | -12.54M | -9.89M | -34.85M | -40M | -27.04M | -24.17M | -2M |
Cash generated by investing activities | -2.07B | -1.02B | -1.87B | -2.75B | -2.11B | 303.42M | -1.58B |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 0 | 1.90B | 0 | 0 | 0 |
Payments for dividends | -358.32M | -333.32M | -285.18M | -397.84M | -739.27M | -814.35M | -735.17M |
Repurchases of common stock | -304.75M | 0 | 0 | 11.89B | -4.26M | 0 | 0 |
Repayments of term debt | -1B | 0 | -1.25B | -11.21B | -294M | -294M | 907M |
Cash used in financing activities | -2.14B | -944.85M | 385.11M | 1.48B | -1.19B | -1.37B | -123.25M |
Net Change In Cash | -1.23B | 169.70M | 532.36M | 763M | -1.64B | 542.64M | -292.64M |
Cash at end of period | 477.01M | 1.71B | 1.54B | 1.00B | 283.68M | 1.92B | 1.38B |
| Data source | Data source | Data source | Data source |